Immune Biomarkers May Predict Bladder Cancer Therapy Response

Researchers at Northwestern Medicine have identified immune system markers that may help predict who responds to BCG bladder cancer therapy and who does not. The findings, published in the Journal of Clinical Investigation, could revolutionize treatment for bladder cancer, the sixth most common cancer in the U.S. BCG therapy, a standard immunotherapy, works by stimulating the immune system to attack cancer cells, but it fails in about 30-40% of patients. By identifying specific biomarkers in the immune system, doctors could tailor treatment plans, avoiding ineffective therapies and their side effects while exploring alternatives like checkpoint inhibitors or oncolytic virus therapies.

This discovery comes as enterprises like Calidi Biotherapeutics Inc. (NYSE American: CLDI) work to further refine immunotherapy approaches. Calidi is developing novel stem cell-based platforms to deliver oncolytic viruses directly to tumors, potentially offering new hope for patients who do not respond to BCG. The biomarker research, combined with innovative therapies from companies like Calidi, underscores a shift toward personalized medicine in oncology. For more details, see the full article on TinyGems: Read More>>

TinyGems, a specialized communications platform under the Dynamic Brand Portfolio @ IBN, is highlighting this breakthrough. TinyGems focuses on innovative small-cap and mid-cap companies with bright futures, providing them with access to a vast network of wire solutions via InvestorWire, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and tailored corporate communications solutions. By cutting through information overload, TinyGems brings clients unparalleled recognition and brand awareness.